Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$6.98
+$0.09 · +1.31%
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Previous close
$6.98
+$0.09 · +1.31%
After-hours
$6.98
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Day range
Current $6.98
52-week range
Current $6.98
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
56
Mixed
Risk
47
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Day range
Current $6.98
52-week range
Current $6.98
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.84M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF667.12K0.00%95.4B USD0.05%$233.13-0.15%
Dimensional - US Small Cap ETFDFAS387.94K0.00%33.66B USD0.31%$78.10+0.23%
U.S. Micro Cap Portfolio ETFDFMC329.15K0.00%7.52B USD0.43%$57.70+0.35%
iShares Micro-Cap ETFIWC188.63K0.01%1.32B USD0.60%$182.79-0.31%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM170K0.15%116.54M USD0.73%$15.90-0.44%
Dimensional - US Targeted Value ETFDFAT96.62K0.00%30B USD0.33%$67.56+0.72%
Dimensional - US Core Equity 2 ETFDFAC59.5K0.00%88.28B USD0.21%$45.11-0.15%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMDimensional - US Targeted Value ETFDFATDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
